CME-Certified 2012 Hematology Tumor Board Series: Practical Solutions to Current Clinical Challenges in B-Cell Lymphoma.

Slides:



Advertisements
Similar presentations
Follicular Lymphoma Transformed Lymphoma Diffuse Large B-Cell Lymphoma
Advertisements

An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.
13th Annual Hematology & Breast Cancer Update Update in Lymphoma
Follicular Lymphoma Laurie H. Sehn, MDCM, MPH BC Cancer Agency Vancouver, Canada.
Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.
Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, :00 PM.
Non-Hodgkin Lymphoma Showing Abnormalities of c-myc Including Dual Translocations Involving c-myc and Bcl-2: A Clinicopathologic Study R Jastania, V Kukreti,
M. BENDARI, M. Rachid, S. Marouane, A. Quessar, S. Benchekroun Department of Hematology-Oncology pediatric Hospital 20 Aout, CHU Ibn Rochd Casablanca.
A 74 year old man underwent open prostatectomy due to moderate to severe urinary symptoms unresponsive to medical therapy. Preoperative PSA was 4.1 Postoperatively.
Treatment of B Cell Malignancies: Current and Emerging Strategies Thomas A. Rado, MD, PhD.
FC and FCR in CLL and Indolent NHL: A descriptive retrospective institutional study Aftimos P, Chahine G Hotel-Dieu de France University Hospital Beirut,
Sequential Dose-Dense R-CHOP Followed by ICE Consolidation (MSKCC Protocol ) without Radiotherapy for Patients with Primary Mediastinal Large B Cell.
Ruan J et al. Proc ASH 2013;Abstract 247.
Copyright © 2011 Research To Practice. All rights reserved. What Clinicians Want to Know A Live CME Event Addressing the Most Common Questions and Controversies.
Cell Suicide in Health and Disease
Bertrand Coiffier Professor, Department of Haematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France Prior posts at the Edouard-Herriot.
ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.
Bladder cancer! By Shamier Daniels. it is a disease in which abnormal cells multiply...
Frontier Pharma Innovative Licensing Opportunities in Non-Hodgkin Lymphoma 2015 Published on : August No. Pages : 115.
Myeloma hope new treatment in the horizon
NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma
Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma
Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group 
Quantitative Nuclear Medicine Imaging
Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell.
Lymphoma NICE guidelines July 2016
National Patterns of Care Study October 2009
Poorer Outcomes With Rituximab + Chemo in Heavier Patients, Older Men With Follicular Lymphoma CCO Independent Conference Highlights of the 2015 ASCO Annual.
Frozen Section/Touch Prep
5th International Symposium October 22nd – 24th, Varese, Italy
Clinical Trials in IBD.
Challenging Cases in Multiple Myeloma Panel Discussion
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Innovations and Issues in Mantle Cell Lymphoma
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.
Updates in Hodgkin Lymphoma
University of Vermont Medical Center
Figure 3 Risk-adapted and response-adapted
Stephen Ansell, MD, PhD Mayo Clinic
by James O. Armitage, and Dan L. Longo
Prolonging Progression-Free Survival in Follicular Lymphoma
CNS involvement in DLBCL
Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas.
BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma
R-CHOP Stem Cell Transplantation for Follicular Lymphoma
How Can we Improve Outcomes for the Elderly Patient with AML?
Treatment Decisions in Chemorefractory Follicular Lymphoma
Jonathan W. Friedberg M.D., M.M.Sc.
Navigating New Oral Treatment Algorithms in CLL
Mutational Testing to Select Novel Targeted Therapies in AML
Treatment guideline and algorithm for Advanced Stage Follicular and Nodal Marginal Zone* Lymphomas All patients should be considered for, and offered,
Made by: reham Talal Khalil Asmaa Mohamed alghefari
Follicular lymphoma : To treat or not to treat, and if so when ?
Caught in transformation
Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.
Pathway for patients with suspected HPB Cancer Inter Provider Transfer
CLL - When to treat, how to treat
Tailoring Therapy in the Newly Diagnosed Patient With CLL
Role for XRT in treatment of early stage Follicular lymphoma?
How to Select Therapy in Relapsed/Refractory CLL
Leticia Quintanilla-Fend LYWS-275 (C646-15)
Treatment guideline and algorithm for Follicular and Nodal Marginal Zone* Lymphomas All patients should be considered for, and offered, NRCN/ MRC clinical.
by Pierre Sesques, and Nathalie A. Johnson
General strategies of Cancer Treatment and evaluation of Response
How I treat early-relapsing follicular lymphoma
Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,
Algorithm for treatment choice in MDS patients after failure of HMA therapy. Algorithm for treatment choice in MDS patients after failure of HMA therapy.
How I treat primary CNS lymphoma
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Optimizing therapy for nodal marginal zone lymphoma
Presentation transcript:

CME-Certified 2012 Hematology Tumor Board Series: Practical Solutions to Current Clinical Challenges in B-Cell Lymphoma

Case 1 Middle-Aged Man With Adenopathy

Case 1 What Would You Recommend for This Patient?

Case 1 What Would You Recommend for This Patient?

Is Watch-and-Wait Still Valid Option in Rituximab Era? Yes!

Watch-and-Wait It Is Critical to Know When the Patient Needs to Be Treated!

Is PET Scan Useful to Help Direct Biopsy? Yes!

At This Point, Patient Needs to Be Treated Does He Need R-Chemo At This Point, Patient Needs to Be Treated Does He Need R-Chemo? If Yes, Which One?

Combination Biologic Therapies Getting More “Mileage” Out of Rituximab Without Chemotherapy

Is Maintenance or Some Form of Consolidation Necessary Is Maintenance or Some Form of Consolidation Necessary? What Should We Do for This Patient at This Point?

Case 2 66-Year-Old Woman With Relapsed/Refractory CLL/SLL

Case 2 How Would You Treat This Patient?

Case 2 Abnormal Cytogenetics

Case 2 What Is Your Recommendation for Treatment Case 2 What Is Your Recommendation for Treatment? What About Novel Agents?

Case 3 69-Year-Old Man With Dysphagia

Case 3 How Would You Treat This Patient?

Case 4 Young Woman With Inguinal Mass

When Is FISH Analysis for MYC Translocations Warranted in Patients With DLBCL? When CD10+ or BCL6+ and 11− and a proliferation index > 80%!

Case 4 Should We Consider CNS Prophylaxis for This Patient?